Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. It's clear from the latest estimates that Esperion Therapeutics' rate of growth is expected to accelerate meaningfully, with the forecast 66% annualised revenue growth to the end of 2023 noticeably faster than its historical growth of 16% p.a. over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 4.8% per year. Factoring in the forecast acceleration in revenue, it's pretty clear that Esperion Therapeutics is expected to grow much faster than its industry.